title: Patients Older Than 65 Years With Non-Hodgkin Lymphoma Are Suitable for Treatment With (90)Yttrium-Ibritumumab Tiuxetan: A Single-Institution Experience.
abstract: BACKGROUND
  The mean age of patients included in clinical trials does not reflect the current clinical practice for patients with B-cell non-Hodgkin lymphoma (B-NHL). We compared our outcomes for patients with B-NHL aged < 65 and > 65 years who were treated with 90-yttrium-ibritumomab tiuxetan therapy ((90)Y-IT).
  
  
  METHODS
  A total of 108 patients who had received (90)Y-IT according to the hospital protocol (ISCRTN36210045) were eligible. A quality of life (QoL) assessment using the Medical Outcomes Study short form 36-item survey was performed for patients aged > 65 years.
  
  
  RESULTS
  Of the 108 patients, 43 were aged > 65 years (mean age, 73.4 years; men 46.15%); 37 had follicular NHL (86.0%). Also, 27 patients had previously undergone < 2 therapy regimens (62.8%). The mean follow-up period was 45.2 months. The mean progression-free survival (PFS) period was 71.3 months, and the mean overall survival was 78.2 months. The median values were not reached. The overall response rate was 90.5%, and a complete response was observed in 36 of the 43 patients aged > 65 years (85.7%). Neutropenia (43.3%) and thrombocytopenia (45.2%) were the most frequent grade 3 and 4 toxicities. Five patients required a red blood cell transfusion and 11, a platelet transfusion. Five patients aged > 65 years (11.6%) developed a second tumor. These outcomes were similar to those for the younger patients. The QoL assessment showed scores similar to those of general population for general health and social functioning.
  
  
  CONCLUSIONS
  This is the largest cohort of NHL treated with RIT in a single institution in Spain. We observed a high response rate and prolonged PFS in patients with B-NHL, independent of patient age. Thus, consolidation RIT offers better outcomes with manageable toxicity.
authors.affiliation: Department of Hematology, Miguel Servet University Hospital, Zaragoza, Spain; Translational Research Unit, Miguel Servet University Hospital-Instituto Aragonés de Ciencias de la Salud, Zaragoza, Spain; Centro de Investigación Biomédica en Red (CIBERER) Instituto de Salud Carlos III, Zaragoza, Spain.
authors.forename: Marcio M
authors.initials: MM
authors.lastname: Andrade-Campos
authors.affiliation: Department of Hematology, Miguel Servet University Hospital, Zaragoza, Spain.
authors.forename: Anel E
authors.initials: AE
authors.lastname: Montes-Limón
authors.affiliation: Department of Hematology, Miguel Servet University Hospital, Zaragoza, Spain.
authors.forename: Gloria
authors.initials: G
authors.lastname: Soro-Alcubierre
authors.affiliation: Department of Nuclear Medicine, Miguel Servet University Hospital, Zaragoza, Spain.
authors.forename: Paola
authors.initials: P
authors.lastname: Lievano
authors.affiliation: Department of Hematology, Royo Villanova Hospital, Zaragoza, Spain.
authors.forename: Luis
authors.initials: L
authors.lastname: López-Gómez
authors.affiliation: Department of Nuclear Medicine, Miguel Servet University Hospital, Zaragoza, Spain.
authors.forename: Teresa
authors.initials: T
authors.lastname: Baringo
authors.affiliation: Translational Research Unit, Miguel Servet University Hospital-Instituto Aragonés de Ciencias de la Salud, Zaragoza, Spain; Centro de Investigación Biomédica en Red (CIBERER) Instituto de Salud Carlos III, Zaragoza, Spain. Electronic address: giraldocastellano@gmail.com.
authors.forename: Pilar
authors.initials: P
authors.lastname: Giraldo
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D016499:Radioimmunotherapy / Q000379:methods*
chemical_list: D000911:Antibodies, Monoclonal; C422802:ibritumomab tiuxetan
keywords: Elderly; Indolent NHL; Quality of life; Radioimmunotherapy; Safety